Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon L Walmsley

Showing results (21-30 of 102) with videos related to

Pageof 11
Sort By:
AIDS (London, England)|July 16, 2019
Drug interactions are not always predictable: the curious case of valproic acid and dolutegravir and a possible explanationAlice L Tseng, Alison Y J Wong, Cassandra J McLelland, et al.
The Journal of Infectious Diseases|September 20, 2005
CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapyMona R Loutfy, Sharon L Walmsley, Christopher M Mullin, et al.
The Journal of Infectious Diseases|March 27, 2012
The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?Jeff E Powis, Janet Raboud, Mario Ostrowski, et al.
AIDS (London, England)|April 14, 2010
Better mind the gap: addressing the shortage of HIV-positive women in clinical trialsAntonella d'Arminio Monforte, Lorena González, Annette Haberl, et al.
AIDS (London, England)|December 31, 2008
Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with menSharon L Walmsley, Kathleen Squires, Laurence Weiss, et al.
The New England Journal of Medicine|March 8, 2002
Clinical problem-solving. Where are you from?Kevin C Katz, Sharon L Walmsley, Anne G McLeod, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2016
HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug DispositionOlena Kis, Sumathi Sankaran-Walters, M Tozammel Hoque, et al.
Trials|November 26, 2010
Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trialDarrell H S Tan, Janet M Raboud, Rupert Kaul, et al.
Journal of the International AIDS Society|October 4, 2013
Caring for women living with HIV: gaps in the evidenceMona R Loutfy, Lorraine Sherr, Ulrike Sonnenberg-Schwan, et al.
Clinical Trials (London, England)|March 16, 2023
Cognitive screening considerations for psychosocial clinical trials in HIV, aging, and cognitionAndrew D Eaton, Soo Chan Carusone, Kate Murzin, et al.
Pageof 11

Showing results (21-30 of 102) with videos related to

Sort By:
Pageof 11
AIDS (London, England)|July 16, 2019
Drug interactions are not always predictable: the curious case of valproic acid and dolutegravir and a possible explanationAlice L Tseng, Alison Y J Wong, Cassandra J McLelland, et al.
The Journal of Infectious Diseases|September 20, 2005
CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapyMona R Loutfy, Sharon L Walmsley, Christopher M Mullin, et al.
The Journal of Infectious Diseases|March 27, 2012
The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?Jeff E Powis, Janet Raboud, Mario Ostrowski, et al.
AIDS (London, England)|April 14, 2010
Better mind the gap: addressing the shortage of HIV-positive women in clinical trialsAntonella d'Arminio Monforte, Lorena González, Annette Haberl, et al.
AIDS (London, England)|December 31, 2008
Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with menSharon L Walmsley, Kathleen Squires, Laurence Weiss, et al.
The New England Journal of Medicine|March 8, 2002
Clinical problem-solving. Where are you from?Kevin C Katz, Sharon L Walmsley, Anne G McLeod, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2016
HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug DispositionOlena Kis, Sumathi Sankaran-Walters, M Tozammel Hoque, et al.
Trials|November 26, 2010
Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trialDarrell H S Tan, Janet M Raboud, Rupert Kaul, et al.
Journal of the International AIDS Society|October 4, 2013
Caring for women living with HIV: gaps in the evidenceMona R Loutfy, Lorraine Sherr, Ulrike Sonnenberg-Schwan, et al.
Clinical Trials (London, England)|March 16, 2023
Cognitive screening considerations for psychosocial clinical trials in HIV, aging, and cognitionAndrew D Eaton, Soo Chan Carusone, Kate Murzin, et al.
Pageof 11